Overview

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety profile of co-administration of BMS-790052 and BMS-650032 for 24 weeks treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Asunaprevir